JP Morgan Chase’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

JP Morgan Chase’s Portfolio IMPL Stock Details IMPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-359	Closed	-$154	–	8009
2023 Q3	$154	Hold	359	–	–	﹤0.01%	6871
2023 Q2	$456	Sell	359 -2,700	-88%	-$4.09K	﹤0.01%	6554
2023 Q1	$4K	Buy	3,059 +2,700	+752%	+$6.44K	﹤0.01%	6321
2022 Q4	$1K	Sell	359 -962	-73%	-$3.51K	﹤0.01%	6473
2022 Q3	$6K	Buy	1,321 +309	+31%	+$2.37K	﹤0.01%	6073
2022 Q2	$9K	Sell	1,012 -4,703	-82%	-$34.4K	﹤0.01%	6061
2022 Q1	$36K	Buy	5,715 +1,618	+39%	+$12.2K	﹤0.01%	5911
2021 Q4	$36K	Buy	4,097 +1,635	+66%	+$16.3K	﹤0.01%	6059
2021 Q3	$30K	Sell	2,462 -4,191	-63%	-$60.8K	﹤0.01%	5969
2021 Q2	$59K	Buy	+6,653	New	+$79.4K	﹤0.01%	5687

Other funds holding IMPL

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

JP Morgan Chase's IMPL Position: Q4 2023 in Review

JP Morgan Chase sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 359 shares — an estimated $154 sold.

JP Morgan Chase first reported a position in IMPL in Q2 2021 and held it in 10 quarters. The position peaked at $59K in Q2 2021. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

JP Morgan Chase reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
JP Morgan Chase sold 359 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $154.
JP Morgan Chase first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 10 quarters.
JP Morgan Chase's Impel Pharmaceuticals Inc. Common Stock position peaked at $59K in Q2 2021.
2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.